Xilio reports Q1 net loss $22.6M; initiates Phase 2 trial for XTX202

Xilio Therapeutics, Inc.

2023-Q1 EPS reported -$0.83

Cash and cash equivalents $93.3M as of Mar 31, 2023; runway into Q2 2024.
Phase 2 trial started for XTX202 (tumor-activated IL-2) in advanced RCC and melanoma.
R&D expenses $16.1M, up from $14.9M, driven by clinical and manufacturing activities.
Net loss $22.6M vs $21.4M in Q1 2022.
Plan to report preliminary Phase 1 data for XTX101 (anti-CTLA-4) in Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Xilio Therapeutics, Inc. reported first quarter ended March 31, 2023 results: net income $22.6 million.

Period: first quarter ended March 31, 2023
Net income: $22.6 million
Result: reported results

Exact text from the filing

Xilio Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2023 and other business highlights.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-008673

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.